{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ostronoff F"],"funding":["NCI NIH HHS"],"pagination":["1157-64"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4372852"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(10)"],"pubmed_abstract":["Purpose
Younger patients with acute myeloid leukemia (AML) harboring NPM1 mutations without FLT3-internal tandem duplications (ITDs; NPM1-positive/FLT3-ITD-negative genotype) are classified as better risk; however, it remains uncertain whether this favorable classification can be applied to older patients with AML with this genotype. Therefore, we examined the impact of age on the prognostic significance of NPM1-positive/FLT3-ITD-negative status in older patients with AML.Patients and methods
Patients with AML age ≥ 55 years treated with intensive chemotherapy as part of Southwest Oncology Group (SWOG) and UK National Cancer Research Institute/Medical Research Council (NCRI/MRC) trials were evaluated. A comprehensive analysis first examined 156 patients treated in SWOG tria"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report."],"pmcid":["PMC4372852"],"funding_grant_id":["T32 CA009515","CA12213","N01 CA032102","U10 CA180819","N01 CA038926","R01 CA160872","U10 CA032102","U10 CA073590","U10 CA020319","CA073590","CA160872","P01 CA018029","U10 CA038926","R01 CA114563","R25 CA174664","U10 CA180888","CA20319","U10 CA180828"],"pubmed_authors":["Othus M","Godwin J","Stirewalt DL","Estey E","Evans A","Lazenby M","Pogosova-Agadjanyan EL","Oehler VG","Meshinchi S","Gilkes A","Radich JP","Willman CL","Kopecky KJ","List AF","Burnett A","Appelbaum FR","Ostronoff F","Fang M","Petersdorf SH"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.","description":"Purpose
Younger patients with acute myeloid leukemia (AML) harboring NPM1 mutations without FLT3-internal tandem duplications (ITDs; NPM1-positive/FLT3-ITD-negative genotype) are classified as better risk; however, it remains uncertain whether this favorable classification can be applied to older patients with AML with this genotype. Therefore, we examined the impact of age on the prognostic significance of NPM1-positive/FLT3-ITD-negative status in older patients with AML.Patients and methods
Patients with AML age ≥ 55 years treated with intensive chemotherapy as part of Southwest Oncology Group (SWOG) and UK National Cancer Research Institute/Medical Research Council (NCRI/MRC) trials were evaluated. A comprehensive analysis first examined 156 patients treated in SWOG tria","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Apr","modification":"2025-05-29T19:40:26.564Z","creation":"2025-05-29T19:40:26.564Z"},"accession":"S-EPMC4372852","cross_references":{"pubmed":["25713434"],"doi":["10.1200/jco.2014.58.0571","10.1200/JCO.2014.58.0571"]}}